Monday, December 10, 2012

Taisho and Novartis KK enter into a comarketing arrangement for TS-071 (SGLT2 inhibitor)

Taisho and Novartis Pharma K.K. , today signed an agreement regarding the licensing of the sales rights in Japan for the marketing of the SGLT2 inhibitor TS-071 (generic name: luseogliflozin hydrate). TS-071 was innovated by Taisho Pharmaceutical and is currently being developed for the treatment of Type 2 diabetes mellitus.

Terms of the Agreement

Under this agreement, TS-071 will be manufactured by Taisho Pharmaceutical, and co-marketed in Japan by Taisho Pharmaceutical Holdings Co. Ltd.’s consolidated subsidiary Taisho Toyama Pharmaceutical Co., Ltd. and Novartis Pharma. As license fees under this agreement, Taisho Pharmaceutical will receive upfront payments and milestone payments from Novartis Pharma.

Currently, Taisho Pharmaceutical is implementing Phase 3 clinical trials in Japan with a planned application for Type 2 diabetes mellitus.


Enter your email address:


Delivered by FeedBurner